The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …

The β common chain cytokines GM-CSF, IL-3, and IL-5 regulate varied inflammatory
responses that promote the rapid clearance of pathogens but also contribute to pathology in …

CD123, the alpha chain of the IL-3 receptor, is an attractive target for acute myeloid
leukemia (AML) treatment. However, cytotoxic antibodies or T cell engagers targeting …

Successful treatment of acute myeloid leukemia (AML) with chimeric antigen receptor (CAR)
T cells is hampered by toxicity on normal hematopoietic progenitor cells and low CAR T cell …

Cancer stem cells (CSCs) are a subpopulation of cells within tumors that possess the stem
cell characteristics of self-renewal, quiescence, differentiation, and the ability to recapitulate …

Natural killer (NK) cells are large granular lymphocytes involved in our defense against
certain virus-infected and malignant cells. In contrast to T cells, NK cells elicit rapid anti …

The emergence of immunotherapy for cancer treatment bears considerable clinical promise.
Nevertheless, many patients remain unresponsive, acquire resistance, or suffer dose …

Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing
evaluation in late-stage clinical studies, which is expected to drive a trend toward first …

Targeted eradication of transformed or otherwise dysregulated cells using monoclonal
antibodies (mAb), antibody–drug conjugates (ADC), T cell engagers (TCE), or chimeric …